[
    [
        {
            "time": "2019-03-24",
            "original_text": "复宏汉霖上市首份年报：研发投入14亿元，亏损8.78亿元",
            "features": {
                "keywords": [
                    "复宏汉霖",
                    "年报",
                    "研发投入",
                    "亏损"
                ],
                "sentiment_score": -0.6,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "生物医药"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "复宏汉霖上市首份年报：研发投入14亿元，亏损8.78亿元",
                "Correlation": 9,
                "Sentiment": 4,
                "Importance": 8,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 8,
                "Market_Scope": 5,
                "Time_Proximity": 7,
                "Headline_Structure": 7,
                "Source_Recency": 8
            }
        },
        {
            "time": "2019-03-24",
            "original_text": "港股异动丨复星医药涨7.75%控股股东增持计划已累计增持0.28%股份",
            "features": {
                "keywords": [
                    "复星医药",
                    "港股",
                    "异动",
                    "增持"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "生物医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "港股异动丨复星医药涨7.75%控股股东增持计划已累计增持0.28%股份",
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 8,
                "Impact": 8,
                "Duration": 5,
                "Entity_Density": 9,
                "Market_Scope": 4,
                "Time_Proximity": 9,
                "Headline_Structure": 8,
                "Source_Recency": 9
            }
        },
        {
            "time": "2019-03-24",
            "original_text": "恒指推出新指数 复星医药（02196）获纳恒生沪深港通生物科技50指数",
            "features": {
                "keywords": [
                    "恒指",
                    "新指数",
                    "复星医药",
                    "生物科技"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "生物医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "恒指推出新指数 复星医药（02196）获纳恒生沪深港通生物科技50指数",
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 8,
                "Impact": 7,
                "Duration": 7,
                "Entity_Density": 8,
                "Market_Scope": 7,
                "Time_Proximity": 7,
                "Headline_Structure": 7,
                "Source_Recency": 8
            }
        },
        {
            "time": "2019-03-24",
            "original_text": "复宏汉霖2019年营收同比增11.25倍 汉丽康销售额达7900万元",
            "features": {
                "keywords": [
                    "复宏汉霖",
                    "营收",
                    "汉丽康",
                    "销售额"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "生物医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "复宏汉霖2019年营收同比增11.25倍 汉丽康销售额达7900万元",
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 8,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 9,
                "Market_Scope": 5,
                "Time_Proximity": 7,
                "Headline_Structure": 8,
                "Source_Recency": 8
            }
        },
        {
            "time": "2020-03-23",
            "original_text": "【山证医药】医药行业周报（20200323）：海外疫情持续蔓延，建议关注原料药等细分领域",
            "features": {
                "keywords": [
                    "医药行业",
                    "周报",
                    "海外疫情",
                    "原料药"
                ],
                "sentiment_score": -0.4,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药",
                    "原料药"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "【山证医药】医药行业周报（20200323）：海外疫情持续蔓延，建议关注原料药等细分领域",
                "Correlation": 5,
                "Sentiment": 6,
                "Importance": 6,
                "Impact": 5,
                "Duration": 5,
                "Entity_Density": 3,
                "Market_Scope": 9,
                "Time_Proximity": 5,
                "Headline_Structure": 6,
                "Source_Recency": 6
            }
        },
        {
            "time": "2019-03-24",
            "original_text": "恒瑞医药交2019年“成绩单”：营收净利均增长超30% 研发叠加政策助力",
            "features": {
                "keywords": [
                    "恒瑞医药",
                    "成绩单",
                    "营收",
                    "净利",
                    "研发",
                    "政策"
                ],
                "sentiment_score": 0.8,
                "policy_related": "true",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "恒瑞医药交2019年“成绩单”：营收净利均增长超30% 研发叠加政策助力",
                "Correlation": 9,
                "Sentiment": 9,
                "Importance": 9,
                "Impact": 9,
                "Duration": 7,
                "Entity_Density": 8,
                "Market_Scope": 5,
                "Time_Proximity": 8,
                "Headline_Structure": 8,
                "Source_Recency": 9
            }
        }
    ]
]